The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndrome

Aliment Pharmacol Ther. 1988 Apr;2(2):167-72. doi: 10.1111/j.1365-2036.1988.tb00684.x.

Abstract

Therapy for diarrhoea associated with the carcinoid syndrome is often unsatisfactory. In an open study ICS 205-930 (Sandoz Limited), a novel 5HT3-antagonist, controlled diarrhoea in five of six patients studied. This drug may be a useful advance in the symptomatic treatment of the carcinoid syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Diarrhea / drug therapy*
  • Diarrhea / etiology
  • Female
  • Humans
  • Indoles / administration & dosage
  • Indoles / therapeutic use*
  • Injections, Intravenous
  • Male
  • Malignant Carcinoid Syndrome / complications*
  • Middle Aged
  • Serotonin Antagonists* / administration & dosage
  • Serotonin Antagonists* / therapeutic use*
  • Tropisetron

Substances

  • Indoles
  • Serotonin Antagonists
  • Tropisetron